Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.5.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash Flows from Operating Activities:    
Net Loss $ (33,032,000) $ (18,953,000)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation expense 74,000 11,000
Noncash interest expense 0 167,000
Amortization of debt discount 423,000 84,000
Amortization of product revenue license fee 21,000 0
Stock-based compensation expense 5,889,000 3,395,000
Issuance of subsidiaries' common shares for license expenses 48,000 0
Financing fees on Helocyte Convertible Note, at fair value 249,000 0
Change in fair value of investments 1,719,000 (1,407,000)
Change in fair value of derivative liabilities 89,000 0
Research and development-licenses acquired, expense 2,095,000 8,629,000
Unrealized loss on marketable securities 0 2,000
Changes in operating assets and liabilities:    
Accounts receivable (967,000) 0
Inventory (100,000) 0
Other receivables - related party (2,414,000) (42,000)
Prepaid expenses and other current assets 195,000 (253,000)
Accounts payable and accrued expenses 3,571,000 920,000
Interest payable (1,000) (2,000)
Other long-term liabilities 3,122,000 (624,000)
Net cash used in operating activities (19,019,000) (8,073,000)
Cash Flows from Investing Activities:    
Purchase of research and development licenses (2,095,000) (8,629,000)
Purchase of property and equipment (4,300,000) (49,000)
Purchase of license (350,000) (1,250,000)
Security deposits collected (1,000) 0
Investment in Origo Acquisition Corp. (175,000) (108,000)
Net cash used in investing activities (6,921,000) (10,036,000)
Cash Flows from Financing Activities:    
Proceeds from exercise of stock options 0 216,000
Proceeds from issuance of common stock under ESPP 81,000 26,000
Proceeds from subsidiary's offering 570,000 0
Proceeds from at-the-market offering 434,000 0
Payment of cost related to at-the-market offering (49,000) 0
Payment of NSC note (2,792,000) 0
Proceeds from NSC note 0 10,000,000
Payment of debt issuance costs associated with NSC Note 0 (855,000)
Proceeds from Helocyte Convertible Note 1,000,000 0
Payment of debt issuance costs associated with Helocyte Convertible Note (150,000) 0
Net cash (used in) provided by financing activities (906,000) 9,387,000
Net decrease in cash and cash equivalents (26,846,000) (8,722,000)
Cash and cash equivalents at beginning of period 98,182,000 49,759,000
Cash and cash equivalents at end of period 71,336,000 41,037,000
Supplemental disclosure of cash flow information:    
Cash paid for interest 158,000 80,000
Supplemental disclosure of non-cash financing and investing activities:    
Issuance of restricted stock 2,000 1,000
Issuance of subsidiaries common shares for license 48,000 0
Issuance of warrants in connection with the Helocyte Convertible Note $ 99,000 $ 0